What question did this study set out to answer?

December 8, 2025BloodOpen Access

Long-term outcomes of patients with hairy cell leukemia treated with first-line cladribine in British Columbia

View Full Paper

Ask AI

Bookmark

Authors

JIJonathan IsenbergBC Cancer Agency LSLaurie H. SehnBC Cancer Agency

Discussion

Member takes

Implication

Population-based analysis shows cladribine improves survival and progression-free survival in hairy cell leukemia, indicating further exploration of second-line therapies is necessary.

Key Points

To evaluate the long-term outcomes of patients with hairy cell leukemia treated with first-line cladribine.
Population-based analysis of HCL patients diagnosed in BC from 1990-2023
Assessment of overall survival, progression-free survival, and treatment patterns at relapse
Comparison of outcomes for patients re-treated with purine analog alone versus with rituximab
Median overall survival from 1L cladribine was 26.6 years
5-year and 10-year progression-free survival rates were 78% and 61%, respectively
Anti-CD20 mAb treatment during second-line therapy resulted in longer progression-free survival compared to purine analog alone

Cite This Study

Isenberg et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d288 https://doi.org/10.1182/blood-2025-1805

View Full Paper

Ask AI

Bookmark

Implication

Population-based analysis shows cladribine improves survival and progression-free survival in hairy cell leukemia, indicating further exploration of second-line therapies is necessary.

Long-term outcomes of patients with hairy cell leukemia treated with first-line cladribine in British Columbia

Discussion

Member takes

Implication

Key Points

Cite This Study

Long-term outcomes of patients with hairy cell leukemia treated with first-line cladribine in British Columbia

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider